HB+ is proud to partner with the National Minority Health Association to help bring about health equity and close the disparity gap in health and healthcare for underserved, marginalized, hard-to-reach, and minority communities.

Using a trial of persons with monoclonal gammopathy of undetermined significance (MGUS), researchers developed a prediction model that accurately predicts the presence of 10 percent or more bone marrow plasma cells (BMPC) and therefore a diagnosis of smoldering multiple myeloma (SMM) or multiple myeloma (MM) by bone marrow criteria in persons presumed to have MGUS.

Read More